Clinical Trial: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema

Brief Summary: The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).